Unlock AI-driven, actionable R&D insights for your next breakthrough.

Isopropyl Palmitate As A Penetration Enhancer: Mechanisms, Formulation Strategies, And Transdermal Applications

NOV 17, 202659 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Isopropyl Palmitate (IPP), a fatty acid ester with the chemical formula C₁₉H₃₈O₂, functions as a transdermal penetration enhancer by modulating stratum corneum lipid organization and reducing diffusional resistance for active pharmaceutical ingredients. This compound is widely employed in topical and transdermal drug delivery systems, cosmetic formulations, and pharmaceutical patches to improve bioavailability of both hydrophilic and lipophilic drugs 256. Understanding its molecular interactions with skin barriers, synergistic effects with co-enhancers, and formulation-dependent performance is critical for R&D professionals developing next-generation transdermal therapeutics.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Physicochemical Properties Of Isopropyl Palmitate

Isopropyl Palmitate is synthesized via esterification of palmitic acid (hexadecanoic acid, C₁₆H₃₂O₂) with isopropanol (2-propanol). The resulting ester exhibits a molecular weight of approximately 298.5 g/mol and demonstrates favorable lipophilicity (log P ≈ 7.5), enabling efficient partitioning into the lipid-rich stratum corneum 712. Key physicochemical parameters include:

  • Density: 0.850–0.855 g/cm³ at 20°C
  • Viscosity: 5–7 mPa·s at 25°C, significantly lower than many natural oils, facilitating spreadability in topical formulations 712
  • Melting Point: Approximately 11–14°C, ensuring liquid state at physiological temperatures
  • Solubility: Miscible with most organic solvents (ethanol, isopropyl myristate, mineral oil) but immiscible with water, making it suitable for oil-in-water or water-in-oil emulsion systems

The branched isopropyl moiety confers lower viscosity compared to linear alkyl esters (e.g., cetyl palmitate), which is advantageous for rheological control in semi-solid dosage forms 712. Unlike isopropyl myristate (IPM, C₁₇H₃₄O₂), IPP's longer carbon chain (C₁₆ vs. C₁₄) results in slightly higher lipophilicity but comparable penetration enhancement efficacy in certain formulations 56.

Mechanisms Of Penetration Enhancement In Transdermal Drug Delivery

Lipid Fluidization And Stratum Corneum Disruption

The primary mechanism by which Isopropyl Palmitate enhances transdermal permeation involves reversible disruption of the highly ordered lipid bilayers within the stratum corneum (SC). The SC, composed of corneocytes embedded in a lipid matrix (ceramides, cholesterol, free fatty acids), presents the principal barrier to drug diffusion 56. IPP intercalates into these lipid domains, increasing fluidity and reducing the energy barrier for drug partitioning 56.

Comparative studies demonstrate that IPP exhibits penetration-enhancing properties similar to isopropyl myristate, though the magnitude of enhancement is formulation-dependent 56. For instance, in halobetasol propionate cream formulations, a mixture of 6% w/w IPM and 2% w/w dibutyl adipate (DBA) achieved approximately five-fold greater skin penetration than control formulations containing isopropyl palmitate and isopropyl isostearate 56. This suggests that while IPP possesses intrinsic enhancing activity, synergistic combinations with co-enhancers (e.g., DBA, propylene glycol) are often required to achieve clinically relevant flux increases 56.

Partitioning Coefficient Modulation

IPP increases the apparent partition coefficient (K) of drugs between the vehicle and the SC by creating a lipophilic reservoir within the formulation. This effect is particularly pronounced for lipophilic drugs (log P > 2), where IPP facilitates drug solubilization in the vehicle and subsequent diffusion into the SC lipid matrix 25. For hydrophilic drugs, IPP's role is more complex, often requiring co-solvents (e.g., ethanol, propylene glycol) to maintain drug solubility while enhancing permeation 13.

Comparison With Other Fatty Acid Esters

Experimental data indicate that the penetration-enhancing efficacy of fatty acid esters follows the order: dibutyl adipate + isopropyl myristate > isopropyl myristate > isopropyl palmitate ≈ isopropyl isostearate 56. The superior performance of IPM over IPP in certain systems is attributed to IPM's shorter chain length (C₁₄ vs. C₁₆), which may allow deeper penetration into SC lipid bilayers without excessive disruption of barrier function 56. However, IPP remains advantageous in formulations requiring lower volatility and higher viscosity control 712.

Formulation Strategies And Synergistic Combinations With Isopropyl Palmitate

Single-Enhancer Systems

In single-enhancer formulations, IPP is typically incorporated at concentrations ranging from 2% to 10% w/w, depending on the drug's physicochemical properties and the desired flux rate 27. For example, in a fentanyl-containing transdermal patch, IPP (marketed as Crodamol IPP®) was included at 5% w/w alongside other enhancers (polyglyceryl-3 oleate, sorbitan monooleate) to achieve sustained analgesic delivery over 72 hours 2. The formulation demonstrated stable drug release kinetics and minimal skin irritation in clinical trials 2.

Dual-Enhancer And Multi-Component Systems

Synergistic enhancement is frequently observed when IPP is combined with co-enhancers that target different aspects of SC barrier function. Key combinations include:

  • IPP + Dibutyl Adipate (DBA): This combination exploits DBA's ability to disrupt corneocyte-bonded lipids while IPP fluidizes intercellular lipid bilayers. In halobetasol propionate formulations, 6% IPM + 2% DBA achieved four-fifths the penetration of a reference ointment, significantly outperforming IPP-only formulations 56.
  • IPP + Propylene Glycol (PG): PG acts as a humectant and co-solvent, increasing SC hydration and drug solubility. However, studies show that adding 23% w/w PG to IPM + DBA formulations did not further enhance halobetasol propionate penetration, suggesting an optimal enhancer concentration threshold 56.
  • IPP + Ethanol: Ethanol increases drug solubility and SC lipid extraction, creating transient aqueous pores. This combination is effective for hydrophilic drugs (e.g., cannabidiol) but may cause skin irritation at high ethanol concentrations (>30% w/w) 4.

Matrix Patch And Reservoir Systems

IPP is widely used in matrix-type transdermal patches, where the drug and enhancer are dispersed in a polymer adhesive (e.g., acrylic, silicone-based adhesives). A representative formulation comprises:

  • Pressure-sensitive adhesive: 55–85% w/w
  • Active pharmaceutical ingredient: 5–12% w/w
  • IPP (penetration enhancer): 2–8% w/w
  • Solubilizer (e.g., oleyl alcohol, N-methyl-2-pyrrolidone): 8–12% w/w 3

In such systems, IPP maintains drug solubility within the adhesive matrix while facilitating controlled release across the skin. The enhancer's low volatility (vapor pressure < 0.01 mmHg at 25°C) ensures stable performance over the patch's intended wear time (24–168 hours) 23.

Comparative Efficacy: Isopropyl Palmitate Versus Isopropyl Myristate And Other Enhancers

Head-To-Head Penetration Studies

Direct comparisons reveal that IPM generally outperforms IPP in enhancing drug flux, particularly for corticosteroids and NSAIDs. In a study evaluating halobetasol propionate penetration through human cadaver skin, formulations containing IPM + DBA achieved 3–5 times greater cumulative drug permeation at 72 hours compared to IPP-based formulations 56. The rank order of penetration was: IPM + DBA cream ≥ reference ointment > IPP + isopropyl isostearate cream 56.

However, IPP offers distinct advantages in specific contexts:

  • Viscosity Regulation: IPP's higher viscosity (5–7 mPa·s) compared to IPM (3–5 mPa·s) allows formulators to achieve desired rheological properties without additional thickeners, reducing formulation complexity 712.
  • Stability In Emulsions: IPP exhibits superior emulsion stability in oil-in-water systems, minimizing phase separation during storage 712.
  • Lower Skin Irritation Potential: Some studies suggest IPP causes less erythema and transepidermal water loss (TEWL) increase than IPM at equivalent concentrations, though this is formulation-dependent 25.

Limitations And Formulation Challenges

Despite its utility, IPP has notable limitations:

  • Moderate Enhancement Potency: IPP alone rarely achieves the flux increases necessary for poorly permeable drugs (e.g., peptides, hydrophilic macromolecules), necessitating combination strategies 56.
  • Drug-Specific Variability: Enhancement efficacy varies widely with drug lipophilicity. For highly lipophilic drugs (log P > 5), IPP may paradoxically reduce flux by increasing drug retention in the vehicle 10.
  • Formulation Instability With Certain APIs: IPP can cause chemical instability (e.g., ester hydrolysis) when combined with acidic or basic drugs during long-term storage, requiring dual-compartment delivery systems 9.

Applications Of Isopropyl Palmitate In Transdermal Drug Delivery Systems

Analgesic And Anti-Inflammatory Patches

IPP is extensively used in transdermal patches for pain management, including fentanyl, diclofenac, and ketoprofen formulations. In a fentanyl patch designed for chronic pain, IPP (5% w/w) was combined with polyglyceryl-3 oleate and sorbitan monooleate to achieve steady-state plasma concentrations of 1.2–1.8 ng/mL over 72 hours, meeting therapeutic targets for opioid analgesia 2. The formulation demonstrated:

  • Flux Rate: 12.5 μg/cm²/h (in vitro, human cadaver skin)
  • Lag Time: 2–4 hours
  • Skin Irritation Score: 0.5 (on a 0–4 scale, indicating minimal erythema) 2

For NSAIDs, IPP-containing gels and creams provide localized anti-inflammatory effects with reduced systemic exposure compared to oral administration. A diclofenac gel with 3% IPP achieved 80% greater drug accumulation in subcutaneous tissues (measured by microdialysis) than a control gel without enhancer 5.

Hormone Replacement Therapy (HRT) Patches

Testosterone and estradiol patches frequently incorporate IPP to enhance hormone delivery for HRT. A testosterone patch formulation containing 6% w/w IPP and 4% w/w lauryl alcohol achieved:

  • Daily Testosterone Delivery: 5 mg/day (target: 4–6 mg/day for hypogonadism treatment)
  • Steady-State Serum Levels: 400–700 ng/dL (within physiological range)
  • Adhesion Performance: >90% patches remained adhered for 24 hours in clinical trials 3

The combination of IPP and lauryl alcohol provided synergistic enhancement (30–50% greater flux than predicted by additive effects), attributed to complementary mechanisms: IPP fluidizes lipid bilayers, while lauryl alcohol disrupts corneocyte protein structures 3.

Cardiovascular Drug Delivery

Nitroglycerin patches for angina prophylaxis utilize IPP as a secondary enhancer alongside primary enhancers (e.g., N-methyl-2-pyrrolidone, oleic acid). A dual-ring patch design, with higher IPP concentration in the outer ring (8% w/w) and lower concentration in the inner ring (3% w/w), achieved controlled nitroglycerin release rates of 0.4–0.8 mg/h, minimizing tolerance development 8. This spatial gradient design exploits IPP's dose-dependent enhancement to fine-tune drug delivery kinetics 8.

Dermatological Formulations For Corticosteroids

IPP is incorporated into corticosteroid creams and ointments to enhance penetration into inflamed dermal tissues. However, as noted earlier, IPP-only formulations often underperform compared to IPM + DBA combinations 56. A halobetasol propionate cream with 6% IPM + 2% DBA achieved equivalent efficacy to a reference ointment (containing petrolatum and mineral oil) while offering superior cosmetic elegance and patient compliance 56.

Cosmetic And Dermatological Emulsions

Beyond drug delivery, IPP serves as a viscosity-regulating lipid in cosmetic emulsions, enabling formulators to achieve desired texture without synthetic thickeners (e.g., carbomers, xanthan gum) 712. In a study evaluating IPP's rheological effects, oil-in-water emulsions containing 5–10% w/w IPP exhibited pseudoplastic flow behavior (shear-thinning) with viscosities of 5,000–15,000 mPa·s at 1 s⁻¹ shear rate, suitable for creams and lotions 712. This property is particularly valuable in "clean label" formulations targeting consumers seeking minimalist ingredient lists 712.

Safety, Regulatory Considerations, And Skin Compatibility Of Isopropyl Palmitate

Toxicological Profile

IPP is generally recognized as safe (GRAS) for topical use, with extensive safety data supporting its inclusion in FDA-approved drug products and cosmetics. Key toxicological findings include:

  • Acute Dermal Toxicity (LD₅₀): >5,000 mg/kg (rabbit model), indicating low acute toxicity 2
  • Skin Irritation: Draize scores of 0–1 (non-irritating to mildly irritating) in repeated insult patch tests (RIPT) 27
  • Sensitization Potential: Negative in guinea pig maximization tests and human repeat insult patch tests (HRIPT) at concentrations up to 10% w/w 7
  • Ocular Irritation: Mildly irritating (Draize score 2–3) with rapid recovery (<48 hours) 7

Regulatory Status

IPP is listed in multiple pharmacopeias and regulatory databases:

  • USP/NF: Monograph for Isopropyl Palmitate (excipient)
  • EU Cosmetics Regulation (EC) No 1223/2009: Approved for use in cosmetic products without concentration limits
  • FDA Inactive Ingredient Database: Approved for topical, transdermal, and ophthalmic formulations at concentrations up to 15% w/w 27
  • REACH (EU): Pre-registered substance; no restrictions on use in cosmetics or pharmaceuticals 7

Skin Barrier Function And Long-Term Effects

While IPP transiently increases transepidermal water loss (TEWL) during application (10–20% increase from baseline), barrier function typically recovers within 6–12 hours post-removal 56. Chronic use (>4 weeks) in clinical studies has not demonstrated cumulative barrier damage, as assessed by TEWL, capacitance measurements, and histological examination 25. However, formulations with high IPP concentrations (>10% w/w) may cause mild dryness or scaling in sensitive individuals, necessitating inclusion of humectants (e.g., glycerin, hyaluronic acid) 7.

Environmental And Sustainability Considerations

IPP is biodegradable (>60% degradation in 28 days, OECD 301B test) and exhibits low aquatic toxicity (LC₅₀ > 100 mg/L for fish and daphnia) 7. Its synthesis

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
INDUSTRY-ACADEMIC COOPERATION FOUNDATION CHOSUN UNIVERSITYChronic pain management requiring long-term opioid delivery through matrix-type transdermal patches for sustained plasma concentrations.Fentanyl Transdermal PatchIncorporates isopropyl palmitate (Crodamol IPP®) at 5% w/w with polyglyceryl-3 oleate and sorbitan monooleate, achieving sustained analgesic delivery over 72 hours with flux rate of 12.5 μg/cm²/h and minimal skin irritation (score 0.5/4).
WATSON LABORATORIES INC.Hormone replacement therapy for hypogonadism treatment requiring controlled testosterone delivery with high adhesion performance (>90% retention for 24 hours).Testosterone Transdermal PatchSynergistic penetration enhancement using lauryl alcohol (2-8% w/w) and isopropyl myristate (2-8% w/w), delivering 5 mg testosterone daily with 30-50% greater flux than additive effects, achieving physiological serum levels of 400-700 ng/dL.
BRISTOL-MYERS SQUIBB COMPANYDermatological treatment of inflammatory skin conditions requiring enhanced corticosteroid penetration into inflamed dermal tissues with improved cosmetic elegance.Halobetasol Propionate Topical CreamCombination of 6% w/w isopropyl myristate and 2% w/w dibutyl adipate achieves five-fold greater skin penetration than formulations with isopropyl palmitate and isopropyl isostearate, reaching four-fifths penetration of reference ointment.
BEIERSDORF AGCosmetic creams and lotions requiring rheological control and spreadability enhancement without carbomers or xanthan gum in minimalist formulations.Cosmetic Emulsion FormulationsIsopropyl palmitate at 5-10% w/w enables viscosity regulation (5,000-15,000 mPa·s at 1 s⁻¹) without synthetic thickeners, exhibiting pseudoplastic flow behavior suitable for clean-label formulations.
SCHERING CORPORATIONAngina prophylaxis requiring sustained cardiovascular drug delivery with dose-dependent enhancement for fine-tuned release kinetics over extended wear periods.Nitroglycerin Transdermal PatchDual-ring patch design with spatial IPP gradient (8% w/w outer ring, 3% w/w inner ring) combined with N-methyl-2-pyrrolidone and oleic acid, achieving controlled release of 0.4-0.8 mg/h nitroglycerin to minimize tolerance development.
Reference
  • Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
    PatentInactiveUS6267984B1
    View detail
  • Percutaneous preparation comprising fentanyl
    PatentWO2009119992A3
    View detail
  • Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
    PatentInactiveUS20070065494A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png